biovet labs inc a los angeles researcher and developer of animal cancer therapy products plans to sell up to 1.2 million common shares in an initial public offering proceeds estimated at 2.5 million will be used for marketing research and development and for general corporate expenditures according to a filing with the securities and exchange commission